{
    "nct_id": "NCT05346484",
    "official_title": "A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).",
    "inclusion_criteria": "* Written informed consent from patient or legally authorized representative\n* Age â‰¥ 18 years old on the date of consent\n* Any metastatic or advanced solid tumor with documented radiological progression following at least two prior lines of treatment (which may have included prior immune checkpoint inhibitor treatment)\n* ECOG performance status 0 - 2\n* At least one measurable lesion\n* Adequate renal function\n* Adequate liver function\n* Adequate hematologic function\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a poxvirus based oncolytic virus.\n* Continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.\n* Prior radiotherapy within 2 weeks of start of study treatment.\n* Active autoimmune disease\n* Prior allogenic tissue/organ transplant or other medical conditions requiring ongoing treatment with immunosuppressive drugs or any condition resulting in a systemic immunosuppressed state\n* Inadequate pulmonary function per Investigator assessment.\n* Uncontrolled brain or other central nervous system (CNS) metastases.\n* History of documented congestive heart failure (New York Heart Association [NYHA] class III - IV), unstable angina, poorly controlled hypertension, clinically significant valvular heart disease or high-risk uncontrolled arrhythmias",
    "miscellaneous_criteria": ""
}